Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Wells Fargo to hold a virtual conference » 08:13
04/07/20
04/07
08:13
04/07/20
08:13
ADAP

Adaptimmune

$3.01 /

+0.38 (+14.45%)

, AFMD

Affimed N.V.

$1.83 /

+0.23 (+14.38%)

, AKCA

Akcea Therapeutics

$15.74 /

+1.19 (+8.18%)

, AGTC

Applied Genetic

$3.38 /

+0.4 (+13.42%)

, ARNA

Arena Pharmaceuticals

$47.33 /

+2.24 (+4.97%)

, AUTL

Autolus Therapeutics

$6.35 /

+1 (+18.69%)

, AVRO

Avrobio

$14.99 /

+1.62 (+12.12%)

, BLUE

Bluebird Bio

$43.52 /

+1.64 (+3.92%)

, CYAD

Celyad

$7.92 /

+0.92 (+13.14%)

, CRSP

Crispr Therapeutics

$42.26 /

+2.81 (+7.12%)

, GRTS

Gritstone Oncology

$6.62 /

+0.36 (+5.75%)

, IMV

IMV Inc.

$1.69 /

+0.03 (+1.81%)

, INFI

Infinity Pharmaceuticals

$0.89 /

+0.0875 (+10.94%)

, JNCE

Jounce Therapeutics

$4.96 /

+0.68 (+15.89%)

, MEIP

MEI Pharma

$1.55 /

+0.07 (+4.73%)

, MNTA

Momenta

$27.93 /

+3.93 (+16.38%)

, MYOK

MyoKardia

$47.96 /

+1.52 (+3.27%)

, QURE

uniQure

$47.77 /

+2.39 (+5.27%)

, VYGR

Voyager Therapeutics

$8.92 /

+0.79 (+9.72%)

2020 Wells Fargo Biotech…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Upgrade
Jounce upgraded to Strong Buy ahead of cancer data at Raymond James » 07:57
03/25/20
03/25
07:57
03/25/20
07:57
JNCE

Jounce Therapeutics

$4.34 /

+0.14 (+3.33%)

Raymond James analyst…

Raymond James analyst Steven Seedhouse upgraded Jounce Therapeutics to Strong Buy from Outperform with an unchanged price target of $11. The analyst believes cancer trials are the least likely to be adversely impacted by COVID-19, given the life-threatening nature of cancer, particularly second-line non-small cell lung cancer. As such, the analyst expects Jounce's EMERGE readout to include clinical and biomarker data from ~40 non-small cell lung cancer patients in the second half of 2020. Seedhouse models a 50% probability of success and he believes shares of Jounce Therapeutics are pricing in "essentially zero" value for the company's pipeline.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Jounce Therapeutics upgraded to Strong Buy from Outperform at Raymond James » 06:27
03/25/20
03/25
06:27
03/25/20
06:27
JNCE

Jounce Therapeutics

$4.34 /

+0.14 (+3.33%)

Raymond James analyst…

Raymond James analyst Steven Seedhouse upgraded Jounce Therapeutics to Strong Buy from Outperform with an $11 price target.

Over a month ago
Earnings
Jounce Therapeutics reports Q4 EPS (68c), may not compare to consensus (28c) » 06:41
02/27/20
02/27
06:41
02/27/20
06:41
JNCE

Jounce Therapeutics

$5.28 /

-0.31 (-5.55%)

Based on its current…

Based on its current operating and development plans, Jounce expects gross cash burn on operating expenses and capital expenditures for the full year 2020 to be approximately $80M-$95M. Jounce will no longer provide license and collaboration revenue guidance as potential future payments under the JTX-8064 license agreement with Celgene are royalty- and milestone-based. Given the strength of its balance sheet, Jounce expects its existing cash, cash equivalents and investments to be sufficient to enable the funding of its operating expenses and capital expenditure requirements through the end of 2021.

ShowHide Related Items >><<
Conference/Events
American Society of Clinical Oncology to hold a symposium » 04:55
02/08/20
02/08
04:55
02/08/20
04:55
JNCE

Jounce Therapeutics

$6.07 /

-0.34 (-5.30%)

, AZN

AstraZeneca

$49.42 /

-0.635 (-1.27%)

, CRVS

Corvus Pharmaceuticals

$4.80 /

-0.495 (-9.35%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, FTSV

Forty Seven

$43.11 /

-0.25 (-0.58%)

, MRK

Merck

$85.09 /

-0.555 (-0.65%)

, NSTG

NanoString

$29.77 /

+0.31 (+1.05%)

ASCO-SITC Clinical…

ASCO-SITC Clinical Immuno-Oncology Symposium will be held in Orlando, FL on February 6-8.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
American Society of Clinical Oncology to hold a symposium » 04:55
02/07/20
02/07
04:55
02/07/20
04:55
JNCE

Jounce Therapeutics

$6.41 /

-0.68 (-9.59%)

, AZN

AstraZeneca

$50.05 /

+0.33 (+0.66%)

, CRVS

Corvus Pharmaceuticals

$5.30 /

+0.485 (+10.08%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, FTSV

Forty Seven

$43.36 /

+1.66 (+3.98%)

, MRK

Merck

$85.65 /

-0.185 (-0.22%)

, NSTG

NanoString

$29.46 /

+1.11 (+3.92%)

ASCO-SITC Clinical…

ASCO-SITC Clinical Immuno-Oncology Symposium will be held in Orlando, FL on February 6-8.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
American Society of Clinical Oncology to hold a symposium » 09:02
02/06/20
02/06
09:02
02/06/20
09:02
JNCE

Jounce Therapeutics

$7.09 /

+0.57 (+8.74%)

, AZN

AstraZeneca

$49.72 /

+0.95 (+1.95%)

, CRVS

Corvus Pharmaceuticals

$4.81 /

-0.58 (-10.76%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, FTSV

Forty Seven

$41.70 /

+1.17 (+2.89%)

, MRK

Merck

$85.83 /

-2.59 (-2.93%)

, NSTG

NanoString

$28.35 /

+0.44 (+1.58%)

ASCO-SITC Clinical…

ASCO-SITC Clinical Immuno-Oncology Symposium will be held in Orlando, FL on February 6-8.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Jounce Therapeutics presents vopratelimab predictive biomarker data » 08:17
02/06/20
02/06
08:17
02/06/20
08:17
JNCE

Jounce Therapeutics

$7.09 /

+0.57 (+8.74%)

, NSTG

NanoString

$28.35 /

+0.44 (+1.58%)

Jounce Therapeutics, Inc.…

Jounce Therapeutics, Inc. (JNCE) announced new data on the identification of the predictive biomarker to be used for patient selection in the SELECT clinical trial of vopratelimab (vopra), in addition to a research collaboration with NanoString (NSTG). The new data introduces TISvopra, a baseline RNA signature with a threshold optimized for the emergence of ICOS hi CD4 T cells, a vopratelimab pharmacodynamic biomarker not associated with PD-1 inhibitor therapy. When applied to ICONIC clinical data, TISvopra predicted clinical outcomes from the ICONIC trial better than PD-L1 immunohistochemistry. Key highlights from the poster, titled "Association of a Predictive RNA Signature With Emergence of ICOS hi CD4 T Cells and Efficacy Outcomes for the ICOS Agonist Vopratelimab and Nivolumab in Patients on the ICONIC trial" include: TISvopra is an 18 gene RNA Tumor Inflammation Signature, utilized with a vopratelimab-specific threshold and was identified as a biomarker predictive of ICOS hi CD4 T cell emergence. TISvopra positive patients treated with vopratelimab alone or in combination with nivolumab also showed improved clinical benefit as compared with TISvopra negative patients in the ICONIC trial. TIS includes genes associated with integral elements of CD4 T cell activation that may contribute to a more comprehensive immune response. The TISvopra threshold was chosen to optimize prediction of ICOS hi CD4 T cell emergence and was more predictive of clinical benefit than PD-L1 IHC in the ICONIC trial. The emergence of ICOS hi CD4 T cells is a vopratelimab, but not a PD-1 inhibitor, pharmacodynamic biomarker linked to clinical benefit in the ICONIC trial. In the upcoming SELECT trial, TISvopra will be used to select patients for treatment with vopratelimab and JTX-4014, Jounce's PD-1 inhibitor. Jounce also announced a research collaboration with NanoString to support the application of the predictive biomarker to be used in the SELECT trial. Under the terms of the collaboration, Jounce and NanoString will apply an optimized selection threshold of the TIS based on the emergence of ICOS hi CD4 T cells. The TISvopra clinical trial assay will be implemented on the nCounter Dx Analysis System.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Jounce Therapeutics appoints Robert Iannone to board of directors » 08:09
01/23/20
01/23
08:09
01/23/20
08:09
JNCE

Jounce Therapeutics

$6.89 /

-0.33 (-4.57%)

, JAZZ

Jazz Pharmaceuticals

$150.45 /

+0.05 (+0.03%)

Jounce Therapeutics…

Jounce Therapeutics (JNCE) announced the appointment of Robert Iannone, M.D., M.S.C.E., to its board of directors. Dr. Iannone serves as the executive vice president, research and development of Jazz Pharmaceuticals (JAZZ), which he joined in May 2019.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
JPMorgan to hold a conference » 10:25
01/16/20
01/16
10:25
01/16/20
10:25
ELGX

Endologix

$1.86 /

+0.01 (+0.54%)

, FPRX

Five Prime

$5.00 /

+0.04 (+0.81%)

, HMSY

HMS Holdings

$29.87 /

+0.64 (+2.19%)

, IDRA

Idera Pharmaceuticals

$1.91 /

+0.035 (+1.87%)

, LXRX

Lexicon

$4.37 /

+0.115 (+2.70%)

, RIGL

Rigel Pharmaceuticals

$3.00 /

+0.27 (+9.89%)

, TRXC

TransEnterix

$1.59 /

-0.03 (-1.85%)

, NVDA

Nvidia

$248.87 /

+3.35 (+1.36%)

, JNCE

Jounce Therapeutics

$7.96 /

+0.275 (+3.58%)

, GRTS

Gritstone Oncology

$11.94 /

+0.6 (+5.29%)

, STRO

Sutro Biopharma

$11.83 /

+ (+0.00%)

, ZIOP

Ziopharm

$5.04 /

+0.09 (+1.82%)

, IMGN

ImmunoGen

$4.93 /

-0.02 (-0.40%)

, ATRC

AtriCure

$36.13 /

+0.79 (+2.24%)

, ACOR

Acorda Therapeutics

$2.14 /

+0.015 (+0.71%)

, ARNA

Arena Pharmaceuticals

$46.25 /

+1.1 (+2.44%)

, KURA

Kura Oncology

$13.02 /

+0.15 (+1.17%)

, NXTC

NextCure

$54.34 /

+0.95 (+1.78%)

, VEEV

Veeva

$146.52 /

+2 (+1.38%)

, RVNC

Revance

$22.84 /

-0.06 (-0.26%)

, ISEE

Iveric bio

$6.81 /

+ (+0.00%)

, INSP

Inspire Medical

$82.38 /

+1.13 (+1.39%)

, CLSD

Clearside Biomedical

$2.45 /

+0.07 (+2.94%)

, MSON

Misonix

$18.93 /

+ (+0.00%)

, KRTX

Karuna Therapeutics

$85.65 /

+0.37 (+0.43%)

38th Annual Healthcare…

38th Annual Healthcare Conference is being held in San Francisco on January 13-16 with webcasted company presentations to begin on January 16 at 10:30 am; not all company presentations may be webcasted. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.